Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/29/2005CA2559722A1 Administration of cisplatin by inhalation
09/29/2005CA2559665A1 Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
09/29/2005CA2559652A1 Methods of using sns-595 in treating cancer
09/29/2005CA2559650A1 Sns-595 and methods of using the same
09/29/2005CA2559646A1 Medicine for prevention or treatment of frequent urination or urinary incontinence
09/29/2005CA2559639A1 Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indasol-6-ylamino]-phenyl}-amide
09/29/2005CA2559629A1 Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
09/29/2005CA2559607A1 Immune response modifier formulations and methods
09/29/2005CA2559553A1 Ether derivatives, their manufacture and use as pharmaceutical agents
09/29/2005CA2559552A1 Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
09/29/2005CA2559545A1 Tetra-cyclic carboline derivatives for inhibiting angiogenesis
09/29/2005CA2559533A1 Phenylaminoethanol derivatives as beta2 receptor agonists
09/29/2005CA2559520A1 Anti-adhesion spraying
09/29/2005CA2559408A1 Carboline derivatives useful in the inhibition of angiogenesis
09/29/2005CA2559310A1 7h-8,9-dihydro-pyrano (2,3-c) imidazo (1,2a) pyridine derivatives and their use as gastric acid secretion inhibitors
09/29/2005CA2559285A1 Methods for the treatment of synucleinopathies
09/29/2005CA2559282A1 Methods for the treatment of synucleinopathies
09/29/2005CA2559276A1 Protocol for improving vision
09/29/2005CA2559229A1 Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
09/29/2005CA2559221A1 Methods for the treatment of synucleinopathies
09/29/2005CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c)
09/29/2005CA2559208A1 Use and administration of bacterial efflux pump inhibitors
09/29/2005CA2559207A1 Salvinorin derivatives and uses thereof
09/29/2005CA2559203A1 Phenylethanolamine derivatives as beta-2 agonists
09/29/2005CA2559200A1 Novel n- (alkoxyalkyl) carbamoyl - substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde3/4 inhibitors
09/29/2005CA2559196A1 Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents
09/29/2005CA2559161A1 Irna agents targeting vegf
09/29/2005CA2559127A1 Methods and compositions for the treatment of conditions related to gastric acid secretion
09/29/2005CA2559105A1 Benzisoxazoles
09/29/2005CA2559047A1 N-substituted benzene sulfonamides
09/29/2005CA2558652A1 Opioid receptor antagonists
09/29/2005CA2558629A1 Trihemihydrate, anhydrate and hydrate forms of cefdinir
09/29/2005CA2558568A1 Opioid receptor antagonists
09/29/2005CA2558389A1 Process for the synthesis of a cxcr4 antagonist
09/29/2005CA2558254A1 Cream-gel containing ivermectin
09/29/2005CA2558169A1 Method of treatment of myocardial infarction
09/29/2005CA2558126A1 The treatment of inflammatory disorders and pain using beta-aminoalcohols
09/29/2005CA2558112A1 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
09/29/2005CA2558096A1 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
09/29/2005CA2558058A1 N-piperidine derivates as ccr3 modulators
09/29/2005CA2558030A1 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
09/29/2005CA2558023A1 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands
09/29/2005CA2558020A1 Use of renin inhibitors in therapy
09/29/2005CA2558015A1 Method for treating aortic stenosis with non-antibacterial tetracycline formulations
09/29/2005CA2558014A1 Antiangiogenic agents
09/29/2005CA2557931A1 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
09/29/2005CA2557929A1 Benzodiazepines for treating or preventing or preventing rsv infection
09/29/2005CA2557836A1 Antisense composition and method for treating cancer
09/29/2005CA2557833A1 Emulsion of fluorocarbon compounds for medical purposes and method for production thereof
09/29/2005CA2557795A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
09/29/2005CA2557730A1 Novel heterocyclyl-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
09/29/2005CA2557443A1 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
09/29/2005CA2557054A1 (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
09/29/2005CA2556917A1 Process for preparing macrocyclic compounds
09/29/2005CA2556915A1 Epothilone derivatives
09/29/2005CA2555363A1 Coenzyme q compositions persisting in blood
09/29/2005CA2555036A1 Antithrombotic compound
09/29/2005CA2554855A1 Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
09/29/2005CA2554637A1 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder
09/29/2005CA2554610A1 Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
09/29/2005CA2554608A1 Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
09/29/2005CA2554555A1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
09/29/2005CA2553933A1 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation
09/29/2005CA2553932A1 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
09/29/2005CA2553208A1 Of at use of an antagonist compound of at least one receptor selected from a group comprising beta-adrenergic receptors, a at1, 5-ht5 and galanin receptor for preparing a pharmaceutical composition for treating rosacea
09/29/2005CA2538289A1 Antibiotic fki-1778 and process for producing the same
09/28/2005EP1580278A1 Process for producing macrolide compound
09/28/2005EP1580266A1 Screening method
09/28/2005EP1580216A1 High-molecular weight derivatives of camptothecins
09/28/2005EP1580194A1 Method of obtaining polymorphic form i of finasteride
09/28/2005EP1580193A2 Eplerenone crystalline form
09/28/2005EP1580192A2 16-Hydroxyestratrienes as selective estrogens
09/28/2005EP1580188A1 Aryl ureas as kinase inhibitors
09/28/2005EP1580183A1 Process for determining the purity of anhydrosugar alcohols
09/28/2005EP1579877A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
09/28/2005EP1579872A1 Body weight gain inhibitor
09/28/2005EP1579864A1 Oxolide antibacterials
09/28/2005EP1579863A2 Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors
09/28/2005EP1579862A1 Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
09/28/2005EP1579861A2 Ointment for nail bed care and for the treatment or prophylaxis of nail bed inflammation and/or inflammation of the nasal mucosa
09/28/2005EP1579860A1 Bone regeneration product for human and veterinary use, containing melatonin as active principle
09/28/2005EP1579859A1 Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
09/28/2005EP1579858A1 Novel use of peptide compounds for treating pain in painful diabetic neuropathy
09/28/2005EP1579857A1 Chemically stable compositions of 4-hydroxy tamoxifen
09/28/2005EP1579856A1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
09/28/2005EP1579198A1 Pharmaceutical compositions with improved dissolution
09/28/2005EP1579010A2 Susceptibility gene for myocardial infarction; methods of treatment
09/28/2005EP1578998A2 Mapks as modifiers of the rac, axin, and beta-catenin pathways and methods of use
09/28/2005EP1578983A2 Methods for regulating co-stimulatory molecule expression with reactive oxygen
09/28/2005EP1578954A2 5' cpg nucleic acids and methods of use
09/28/2005EP1578931A2 Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinase
09/28/2005EP1578926A2 Novel prostate tumor-specific promoter
09/28/2005EP1578924A2 Genomic screen for epigenetically silenced tumor suppressor genes
09/28/2005EP1578922A2 Replikin peptides in rapid replication of glioma cells and in influenza epidemics
09/28/2005EP1578919A2 Endogenous retrovirus up-regulated in prostate cancer
09/28/2005EP1578918A2 Atherosclerotic phenotype determinative genes and methods for using the same
09/28/2005EP1578915A2 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
09/28/2005EP1578908A2 Human schizophrenia gene
09/28/2005EP1578898A2 Nad synthetase inhibitors and uses thereof
09/28/2005EP1578897A2 Process for inducing functional tolerance to gene transfer products
1 ... 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 ... 7860